The results showed that 38.5% of patients with TNBC exhibited high GSDMC expression in tumor tissue (Figure 1A, Table 1, and Supplemental Figure 1; supplemental material available online with this article; https://doi.org/10.1172/JCI166841DS1), which, interestingly, showed better response to PARPi therapy (Table 2). This evidence concerns the gene GSDMC and neoplasm.